173 related articles for article (PubMed ID: 870178)
1. Pharmacology of 5'-esters of 1-beta-D-arabinofuranosylcytosine.
Ho DH; Neil GL
Cancer Res; 1977 Jun; 37(6):1640-3. PubMed ID: 870178
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
[TBL] [Abstract][Full Text] [Related]
3. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
Hong CI; Bernacki RJ; Hui SW; Rustum Y; West CR
Cancer Res; 1990 Jul; 50(14):4401-6. PubMed ID: 2364392
[TBL] [Abstract][Full Text] [Related]
4. Production of N4-succinyl-1-beta-D-arabinofuranosylcytosine, a novel metabolite of N4-behenoyl-1-beta-D-arabinofuranosylcytosine, in mice and its biological significance.
Oh-ishi J; Kataoka T; Tsukagoshi S; Sakurai Y; Shibukawa M; Kobayashi H
Cancer Res; 1981 Jun; 41(6):2501-6. PubMed ID: 7237444
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate-induced changes in the levels of 1-beta-D-arabinofuranosylcytosine triphosphate in L1210 cells.
Roberts D; Peck C; Hilliard S; Wingo W
Cancer Res; 1979 Oct; 39(10):4048-54. PubMed ID: 476642
[TBL] [Abstract][Full Text] [Related]
7. Metabolism and selective effects of 1-beta-D-arabinofuranosylcytosine in L1210 and Host tissues in vivo.
Chou TC; Hutchinson DJ; Schmid FA; Philips FS
Cancer Res; 1975 Jan; 35(1):225-36. PubMed ID: 1109791
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of tumor cell growth in vitro and in vivo by 1-beta-D-arabinofuranosylcytosine entrapped within phospholipid vesicles.
Mayhew E; Papahadjopoulos D; Rustum YM; Dave C
Cancer Res; 1976 Dec; 36(12):4406-11. PubMed ID: 187321
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of the new liposomal anticancer drug N4-octadecyl-1-beta-D-arabinofuranosylcytosine in mice.
Koller-Lucae SK; Suter MJ; Rentsch KM; Schott H; Schwendener RA
Drug Metab Dispos; 1999 Mar; 27(3):342-50. PubMed ID: 10064564
[TBL] [Abstract][Full Text] [Related]
10. Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia.
Colly LP; Peters WG; Willemze R
Cancer Res; 1986 Aug; 46(8):3825-7. PubMed ID: 3460691
[TBL] [Abstract][Full Text] [Related]
11. Therapy of central nervous system leukemia in mice by liposome-entrapped 1-beta-D-arabinofuranosylcytosine.
Hong F; Mayhew E
Cancer Res; 1989 Sep; 49(18):5097-102. PubMed ID: 2766280
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine.
Neil GL; Berger AE; Bhuyan BK; DeSante DC
Cancer Res; 1976 Mar; 36(3):1114-20. PubMed ID: 56229
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
Ueda T; Kamiya K; Urasaki Y; Wataya S; Kawai Y; Tsutani H; Sugiyama M; Nakamura T
Cancer Res; 1994 Jan; 54(1):109-13. PubMed ID: 8261429
[TBL] [Abstract][Full Text] [Related]
15. [Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].
Nagahata T; Shibasaki C; Ishii T; Uchida T; Arakawa M; Kusama K; Ekimoto H; Takahashi K
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1437-45. PubMed ID: 2389942
[TBL] [Abstract][Full Text] [Related]
16. Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability.
Matsushita T; Ryu EK; Hong CI; MacCoss M
Cancer Res; 1981 Jul; 41(7):2707-13. PubMed ID: 7248939
[TBL] [Abstract][Full Text] [Related]
17. Effect of methotrexate and 1-beta-D-arabinofuranosylcytosine on pools of deoxyribonucleoside triphosphates in L1210 ascites cells.
Roberts D; Peck C
Cancer Res; 1981 Feb; 41(2):505-10. PubMed ID: 7448798
[TBL] [Abstract][Full Text] [Related]
18. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
Liliemark JO; Plunkett W; Dixon DO
Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
[TBL] [Abstract][Full Text] [Related]
19. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of mouse leukemia L1210 by 1-beta-D-arabinofuranosylcytosine and 6-[(4-nitrobenzyl)thio]-9-beta-D-ribofuranosylpurine.
Cass CE; Muzik H; Paterson AR
Cancer Res; 1975 May; 35(5):1187-93. PubMed ID: 1120308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]